Insilico Medicine’s AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy Post author: Post published:April 14, 2024 Post category:uncategorized In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. You Might Also Like AI predicts glaucoma progression in high-risk patients with high accuracy November 3, 2023 Addressing the mental health crisis among prostate cancer patients August 6, 2024 Asian health center tries unconventional approach to counseling October 9, 2024